Dr. Ketan Badani MD - New York

About Dr. Ketan Badani

World-renowned for his expertise in minimally invasive robotic surgery, Dr. Ketan Badani is one of the foremost urologists of his generation. He has performed more than 4000 robotic surgical procedures. The independent Consumers Research Council of America consistently lists him in its "America's Top Urologists" and "America's Top Surgeons," and he is Castle Connolly and New York Magazine's "Top Doctor" in 2014.

Top doc

A medical pioneer, Dr. Badani led the elite surgical team that first developed and published techniques for minimally invasive robotic kidney cancer surgery. He has focused his work on prostate and kidney cancer, and leads a team seeking to improve surgical treatment of these cancers by finding less invasive and effective therapy while maintaining quality of life factors after surgery. Dr. Badani has more combined experience in robotic prostate and kidney cancer surgery than any other doctor in New York.

A gifted communicator who lectures throughout the world, Dr. Badani trains doctors on five continents in these cutting-edge procedures. He is the professor of urology at Icahn School of Medicine at Mount Sinai Hospital; vice chairman of urology, director of robotic surgery for Mount Sinai, St. Luke’s, and Roosevelt Hospitals; and director of the Comprehensive Kidney Cancer Program at Mount Sinai. Dr. Badani was most recently the director of robotic surgery and director of research for prostate and kidney cancer outcomes at Columbia University Medical Center for 7 years.

Dr. Badani is the author of over 150 peer-reviewed publications and has presented over 200 abstracts at national and international meetings. He also co-wrote the book Robotic Prostatectomy for Prostate Cancer -- Is It for You?. He frequently appears on radio and television.

Practicing high tech, high compassion medicine

Growing up with computers sparked Dr. Badani's passion for high tech medicine, leading him to train with Dr. Mani Menon at the prestigious Vattikuti Urology Institute in Detroit, Michigan, where robotic prostatectomy originated.

At the NYC Robotic Institute at Mount Sinai Health System, Dr. Badani leads a team of over 20 that includes highly-trained doctors, skilled surgical nurses, surgical technicians, and administrative personnel committed to excellence. "Every time there is a promising new technology available, my team is the first to study and research it carefully to determine if it is of benefit to patients," he says. But it is his unwavering dedication to patient care that guides Dr. Badani's leadership of the department. "The robot is nothing magical," he says. "It is only a tool—just like a scalpel. What sets us apart is our expertise and our compassion for the people we treat."

Dr. Badani acknowledges that a cancer diagnosis can be very scary. Men are concerned about intimate subjects. "How will surgery affect my sex life?" is one of the most common questions he hears from patients. "Today, younger and younger men are being treated for prostate cancer," he explains. "They have a long life expectancy ahead. So certainly quality of life is very important."

Minimal pain, maximum results

Minimally-invasive surgery using the da Vinci robot allows patients to have better outcomes. Dr. Badani's published research shows that patients treated with his methods have shorter hospital stays, experience less blood loss and pain, have smaller incisions and return to their normal routines sooner. And, in the case of robotic prostatectomy, their risk for impotency and incontinence is reduced.

These positive results, coupled with Dr. Badani's genuine compassion, have earned him the admiration and gratefulness of those under his care. "I have a very long-lasting relationship with my patients," he says. "Even though we're able to minimize trauma to the body and get patients home quickly, the relationship lasts a lifetime."

Dr. Badani will help lead Mount Sinai Health as the foremost center in the New York area with his robust experience in the treatment of prostate and kidney cancer, innovative technology-based research, and unrelenting drive to improve patient outcomes.